BEST UNLIMITED TURBO LONG CERTIFICATE - NOVO-NORDISK B | Market Closed - Euronext Paris 10:00:00 03/05/2024 pm IST | ||
| 18.72 EUR | -3.88% |
|
| Current month | -6.02% | ||
| 1 month | -4.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 18.72 | -3.88% | 120 |
| 02/24/02 | 19.47 | -2.20% | 116 |
| 30/24/30 | 19.91 | +1.32% | 118 |
| 29/24/29 | 19.65 | -0.45% | 113 |
| 26/24/26 | 19.74 | +2.95% | 118 |
Real-time Euronext Paris
Last update May 03, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| CD06Z | |
| ISIN | DE000CJ3P4M8 |
| Date issued | 09/11/2018 |
| Strike | 154.5 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.25 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.42 € |
|---|---|
| Lowest since issue | 0.165 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
850.6
DKK
Average target price
908.4
DKK
Spread / Average Target
+6.80%
- Stock Market
- Certificates
- CD06Z Certificat